Related Experiment Videos
Prostaglandins in the rheumatic diseases
Annals of the New York Academy of Sciences
|June 13, 1975
Summary
Prostaglandins, specifically prostaglandin E2 (PGE2), are key players in inflammatory rheumatic diseases, driving inflammation and bone loss. Treatments that inhibit prostaglandin synthesis show reduced levels in patients.
Area of Science:
- Biochemistry
- Rheumatology
- Immunology
Background:
- Prostaglandins (PGs) are implicated in the pathogenesis of inflammatory rheumatic diseases.
- PGs may act as mediators of inflammation and promote bone resorption.
Purpose of the Study:
- To investigate the role of prostaglandins in inflammatory rheumatic diseases.
- To compare prostaglandin levels in patients with inflammatory rheumatic diseases versus controls.
Main Methods:
- Measurement of prostaglandin levels (PGE2) in synovial fluids and organ cultures of rheumatoid synovium.
- Assessment of bone-resorbing activity in vitro using mouse calvaria.
- Inhibition studies using indomethacin.
Main Results:
- Elevated prostaglandin B (PGB) levels in synovial fluids of patients with inflammatory rheumatic diseases compared to controls.
- Rheumatoid synovium produces significant amounts of PGE2 in organ culture.
- Fibroblast cell lines from rheumatoid synovia synthesize more PGE and cAMP than normal cells.
- Synovial organ cultures exhibit bone-resorbing activity, which is attributed to PGE2 and inhibited by indomethacin.
Conclusions:
- Prostaglandin E2 (PGE2) is a significant mediator in the pathogenesis of inflammatory rheumatic diseases.
- PGE2 contributes to both inflammation and bone resorption in these conditions.
- Inhibition of PG synthesis may be a therapeutic strategy for inflammatory rheumatic diseases.